I-Mab
NASDAQ: IMAB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xi-Yong Fu
- Employees
- 32
- Headquarters
- Rockville, United States
- IPO year
- 2020
- Market cap
- $542.0M
- Website
- https://www.i-mabbiopharma.com
Loading IMAB…
Loading profile data…Frequently asked questions about IMAB
What does I-Mab (IMAB) do?
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates. Among its most advanced progra...
Where does IMAB trade?
I-Mab (IMAB) trades on the NASDAQ Global Market.
What sector is IMAB in?
I-Mab (IMAB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of I-Mab?
Xi-Yong Fu is the chief executive officer of I-Mab (IMAB).
Where is I-Mab headquartered?
I-Mab is headquartered in United States.
Does IMAB pay a dividend?
I-Mab (IMAB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMAB go public?
I-Mab (IMAB) completed its initial public offering in 2020.
Is IMAB an ADR?
Yes — IMAB is an American Depositary Receipt; its underlying shares trade on a non-US exchange. I-Mab reporting and dividends follow the underlying issuer.